Canaccord lowered the firm’s price target on Edwards Lifesciences to $85 from $86 and keeps a Buy rating on the shares. The firm said TAVR sales were slightly below consensus estimates as management noted lower billing days, but TMTT performance was strong.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- EW Upcoming Earnings Report: What to Expect?
- Edwards Lifesciences price target raised to $101 from $95 at RBC Capital
- Edwards Lifesciences price target raised to $105 from $95 at Mizuho
- SMART data a ‘modest win’ for Medtronic, says Jefferies
- Edwards Lifesciences price target raised to $98 from $90 at Citi
